The new model of domestic BD!

On January 18, Shanghai Heyu Pharma announced that it has reached a global cooperation and exclusive license agreement with Eli Lilly.
innovative treatments in the field
.

The cooperation project between Heyu Pharma and Eli Lilly has reached a milestone payment of 258 million US dollars, and from the early stage of drug development, it fully reflects the strong R&D strength of Heyu Pharma and the value of the world's leading pharmaceutical company, Lilly, to Heyu Pharma.
's approval
.

At the same time, it also represents the confidence of both parties in the market space of indications covered by this target in the future

Joining forces with domestic and foreign BD cooperation new model

Joining forces with domestic and foreign BD cooperation new model

It is understood that the research and development stage of the molecules involved by the two parties is still in the very early stage.
The two parties will use this as a starting point to invest their own advantageous resources and jointly participate in the project research and development process, so as to achieve long-term cooperation throughout the entire life cycle of the drug, and jointly enjoy research and development.
Global equity in outcomes
.

The specific form of cooperation is to rely on Heyu Pharma's proprietary drug discovery platform.
According to some existing basic research of Eli Lilly and its knowledge and experience in related diseases, targets and drug discovery, Heyu Pharma will lead the development from lead compounds to PCC clinical trials.
Discovery of candidate compounds
.

In the follow-up, the two parties will select the R&D products according to the cooperation terms, and select suitable targets for subsequent development and commercialization

It is reported that the cooperation between the two parties will focus on a global innovative first-in-class target.
No domestic company has similar projects, and the market potential is huge
.

The cooperation between the two parties will focus on a global innovative first-in-class target.
No domestic company has similar projects, and the market potential is huge.

Compared with the previous license in/out and other types of cooperation between domestic companies and large overseas pharmaceutical companies, the cooperation model between Heyu Pharma and Eli Lilly is the first time
.

The cooperation model between Heyu Pharma and Eli Lilly is the first time

Dr.
Xu Yaochang, CEO of Heyu Pharma, said, "We are delighted to use Heyu's independent R&D platform to work together to advance this project to the development stage through in-depth cooperation with the Eli Lilly team
.

This cooperation represents a major international pharmaceutical company.

Focus on the innovative road of small molecule R&D pharmaceutical companies

Focus on the innovative road of small molecule R&D pharmaceutical companies

The innovative small molecule R&D platform of Heyu Pharma has been widely concerned in the industry
.

In the past five years, Heyu Pharma has established a world-class R&D engine, with an average rate of 2 preclinical R&Ds per year, and has launched 10 candidate drug molecules in the past five years , including 4 that have entered the clinical trial stage.

Preclinical research and development at an average rate of 2 per year, and has launched 10 drug candidates since its establishment more than five years ago.

Heyu Medicine's tumor precision treatment pipeline

Heyu Pharma's proprietary small molecule drug innovation R&D platform enables cancer genomics and screening, computational medicinal chemistry, translational and biomarker science for the discovery of differentiated and innovative oncology therapies
.

It is expected to discover more potential preclinical drug candidates and expand the multiple targets that can be used in combination

In order to cover more indications and provide better treatment options, Heyu Pharma uses its own drug research and development platform to combine its core products and other clinical-stage drug candidates to form a portfolio of small molecule tumor treatment candidates
.

In terms of small molecule immunotherapy drugs, Heyu Pharma's targets have covered CSF-1R, CXCR4, PD-L1, CD73 and RORγt

Heyu Medicine’s Tumor Immunotherapy Pipeline

Among them, the CSF-1R inhibitor ABSK021 is used for the treatment of macrophage-dependent diseases.
It has a wide range of indications and is in Phase Ib clinical trials.
Phase Ib clinical trials are being carried out in China and the United States
.

The small-molecule PD-L1 inhibitor ABSK043, which can specifically bind to PD-L1, leading to PD-L1 dimerization, conformational change and internalization on the cell surface, is currently conducting a phase Ia clinical trial in Australia

In addition, two preclinical projects are the CD73 inhibitor ABSK051 and the RORγt antagonist ABSK031, of which ABSK051 is preparing to apply for clinical trials in 2022
.

At present, the indications of Heyu Pharmaceutical's pipeline products cover lung cancer, gastric cancer, liver cancer, breast cancer, urothelial cancer, pancreatic cancer and other tumors, and the patient base is very large
.

Co-expansion and innovation to accelerate the pace of internationalization

Co-expansion and innovation to accelerate the pace of internationalization

Different from the conventional buy-and-sell cooperation in which domestic pharmaceutical companies sell the commercialization rights of innovative drugs in a specific period or in a specific region, the agreement between Heyu Pharma and Eli Lilly has created a new model of early innovation, showing that Heyu Pharma is unswervingly exploring Innovation and determination to go global have also provided a new paradigm for Chinese pharmaceutical companies to pursue innovative research and development
.

Through the multi-faceted close cooperation with Eli Lilly, Heyu will move towards first-in-class innovation faster, accumulate R&D reserves, and enjoy the fruits of global commercialization of innovative drugs
.

This collaboration will help Heyu Pharma expand its product pipeline into new disease areas with significant demand
.
Based on the close connection between this specific target and various diseases such as cardiovascular and metabolic diseases, Heyu Medicine will closely connect its own R&D platform with Eli Lilly's expertise in related disease fields, and help Heyu expand to other other diseases based on tumor research.
Disease areas with huge clinical needs
.
Obviously, with the blessing of the international giant Lilly, this will greatly improve the efficiency and success of Heyu's exploration in this direction
.

In addition, by cooperating with Eli Lilly, Heyu Pharma has the inherent advantage of developing innovative R&D synchronously around the world, which accelerates the process of the company's internationalization
.
Heyu Pharmaceutical has a unique drug research and development platform "differentiated research and development + international layout", which is expected to stand out in the innovation wave
.

While focusing on independent research and development of innovative drugs, Heyu Pharma has already adopted various methods to fully carry out global cooperation, constantly explore more novel and globally valuable cooperation models, actively expand product pipelines and explore the potential of combination drugs of candidate products
.

For example, Heyu Pharma has partnered with Roche to combine ABSK011 with the PD-L1 antibody atezolizumab in the treatment of advanced hepatocellular carcinoma
.
In July last year, it also licensed the development rights of ABSK021 for the treatment of amyotrophic lateral sclerosis (ALS) in Greater China to Shufang Medicine
.
In addition, Heyu Pharma has also reached commercialization cooperation agreements with AstraZeneca and Shanghai Pharmaceuticals
.

As a pioneer in the innovation of cooperation model, this innovative form of R&D cooperation between Heyu Pharmaceutical and Eli Lilly has been reached.
This time, the two parties can integrate resources in drug R&D.
strength in the field of medicine
.

Can this BD transaction bring a new development direction to industry cooperation? We will wait and see
.